`CONTACTS: For NACo: Brian Namey, bnamey@naco.org, 202.942.4220
`For NGA: Elena Waskey, ewaskey@nga.org, 202.624.5301
`For NLC: Tom Martin, martin@nlc.org, 202.626.3186
`For USCM: Elena Temple-Webb, etemple@usmayors.org, 202.286.1100
`
`State, local leaders expand efforts to treat
`opioid overdoses
`Cooperative purchasing effort to offer public agencies discounted
`access to newly-approved treatment
`
`WASHINGTON, D.C. – As the White House Office of National Drug Control Policy hosts a community
`forum on the opioid epidemic in Knox County, Tenn., state and local leaders today announced an
`expansion of efforts to facilitate public agencies’ access to potentially lifesaving opioid withdrawal
`medication.
`
`The National Association of Counties, National Governors Association, National League of Cities and
`United States Conference of Mayors, with the U.S. Communities Government Purchasing Alliance and
`Premier, Inc., have reached an agreement with Adapt Pharma to offer Narcan® Nasal Spray at a 40-
`percent discount, or $37.50 per dose ($75 for a 2 pack carton).i
`
`Narcan Nasal Spray, is the only FDA-approved, ready-to-use nasal spray version of naloxone
`hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose.
`
`“The Administration has made it a top priority to expand access to the overdose reversal drug naloxone
`and medication-assisted treatment because we have lost too many of our family members and friends
`to the opioid epidemic,” said White House National Drug Policy Control Director Michael Botticelli.
`“This public-private partnership to secure discounts for state and local agencies can help ensure that
`these life-saving medications are available wherever they are needed.”
`
`“Governors are at the forefront of the fight against opioid abuse,” said National Governors Association
`(NGA) Chair Utah Governor Gary Herbert. “At the last NGA Summer Meeting, governors convened to
`discuss the opioid epidemic. There we discussed that to turn the tide, there must be a coordinated
`response across all levels of government, which this purchasing effort helps to achieve.”
`
`-- more --
`
`Opiant Exhibit 2150
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 1
`
`
`
`“Medication-assisted opioid treatment can mean the difference between life and death,” said National
`Association of Counties President Sallie Clark, commissioner, El Paso County, Colo. “We see the
`devastating effects of prescription drug abuse and heroin use because counties are at the intersection of
`the local health, justice and public safety systems. We welcome this public-private partnership to
`support our response to this national crisis.”
`
`As part of its Safe and Secure Counties Initiative, NACo is working with state associations of counties to
`develop policy recommendations and promote promising practices to address the opioid epidemic
`plaguing communities.
`
`“American cities are facing an epidemic of opioid addiction. Providing affordable access to drugs like
`Narcan Nasal Spray is critical to saving lives in the event of an opioid overdose,” said Clarence Anthony,
`CEO and executive director of the National League of Cities. “This public-private partnership is a vital
`step in stemming the opioid addiction epidemic in our communities.”
`
`“Mayors across this nation are grappling with solutions to address the exponential rise in opioid
`overdoses occurring in our cities. We believe the expanded availability of this treatment is another tool
`for mayors and cities to use in their efforts to stem this epidemic,” stated U.S. Conference of Mayors
`CEO & Executive Director Tom Cochran.
`
`
`Announced at the organization's Fall Leadership Meeting, Conference of Mayors President Baltimore
`Mayor Stephanie Rawlings-Blake created a special mayors’ task force on substance abuse, prevention
`and recovery services, which will be headed by Boston Mayor Martin Walsh.
`
`In October 2015, the U.S. Communities Purchasing Alliance, which pools the purchasing power of more
`than 62,000 agencies in state and local government and the non-profit sector, made available naloxone
`and medications containing buprenorphine. This latest announcement expands the offering to include
`Narcan.
`
`For more information including Narcan Nasal Spray prescribing information, safety information, photos
`and videos click here.
`
`# # #
`
`The National Association of Counties (NACo) unites America’s 3,069 county governments. Founded in 1935, NACo brings
`county officials together to advocate with a collective voice on national policy, exchange ideas and build new leadership skills,
`pursue transformational county solutions, enrich the public’s understanding of county government and exercise exemplary
`leadership in public service. More information at: www.naco.org.
`
`The National Governors Association (NGA), founded in 1908, is the collective voice of the nation’s governors and one of
`Washington, D.C.’s most respected public policy organizations. Its members are the governors of the states, territories and
`commonwealths. NGA provides governors and their senior staff members with services that range from representing states on
`Capitol Hill and before the Administration on key federal issues to developing and implementing innovative solutions to public
`policy challenges through the NGA Center for Best Practices. For more information, visit www.nga.org.
`
`The National League of Cities (NLC) is dedicated to helping city leaders build better communities. NLC is a resource and
`advocate for 19,000 cities, towns and villages, representing more than 218 million Americans.
`
`The U.S. Conference of Mayors is the official nonpartisan organization of cities with populations of 30,000 or more. There are
`nearly 1,400 such cities in the country today, and each city is represented in the Conference by its chief elected official, the
`mayor. Like us on Facebook at facebook.com/usmayors, or follow us on Twitter at twitter.com/usmayors.
`
`i Subject to terms and conditions including minimum order.
`
`Opiant Exhibit 2150
`Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
`IPR2019-00688
`Page 2
`
`